Xuanzhu Biopharmaceutical Co., Ltd.

Beijing Xuanyi Pharmasciences Co., Ltd.

Beijing Xuanzhu Combio Co., Ltd.

Ping Hui Szu

Yuntao Song

Chen Dong

Yi Ding

John Lippincott

Jianhui Zhou

Zhiwei Li

The present disclosure provides variant CD80 polypeptides that have altered affinity for their cognate binding partners, and immunomodulatory fusion proteins comprising the variant CD80 polypeptides. The present disclosure also provides pharmaceutical compositions comprising such polypeptides and/or proteins and methods for modulating immune responses and/or treatment of cancer, infectious diseases, and/or immunological diseases.

CD80 variant proteins and uses thereof

Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.

Anti-claudin 18.2 antibodies

Growing community of inventors

Walnut Creek, CA, United States of America

Ping Hui Szu